Detalhe da pesquisa
1.
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
N Engl J Med
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38785209
2.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
N Engl J Med
; 389(26): 2436-2445, 2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921461
3.
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Circulation
; 149(6): 450-462, 2024 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952217
4.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 149(23): 1789-1801, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583093
5.
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
J Am Soc Nephrol
; 35(1): 74-84, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088558
6.
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
J Am Soc Nephrol
; 35(3): 311-320, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38261535
7.
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation
; 148(8): 651-660, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37603600
8.
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Kidney Int
; 105(1): 189-199, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914086
9.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet
; 401(10388): 1584-1594, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015244
10.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet
; 402(10417): 2077-2090, 2023 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931634
11.
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
N Engl J Med
; 385(25): 2325-2335, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739194
12.
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
N Engl J Med
; 385(25): 2313-2324, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739196
13.
Combination therapy with kidney protective therapies: optimizing the benefits?
Curr Opin Nephrol Hypertens
; 33(1): 136-143, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767945
14.
Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Am J Kidney Dis
; 83(3): 350-359.e1, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37777059
15.
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38807510
16.
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
J Am Soc Nephrol
; 34(12): 2025-2038, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37872654
17.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol
; 34(12): 1965-1975, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37876229
18.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation
; 145(8): 575-585, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903039
19.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35394821
20.
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
Kidney Int
; 104(1): 181-188, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37119876